Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.36 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.35 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.34 |
| ▸ | FURIN | P09958 | 5/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 3/20 | 0.32 |
| ▸ | NPY1R | P25929 | 2/20 | 0.32 |
| ▸ | NPY2R | P49146 | 2/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20375659 | 1.00 | SIRT5 (0.36) | SIRT5KISS1RC3AR1FURINSIRT6 | |
| SCHEMBL21103418 | 1.00 | SIRT5 (0.36) | SIRT5KISS1RC3AR1FURINSIRT6 | |
| SCHEMBL18661755 | 1.00 | SIRT5 (0.36) | SIRT5KISS1RC3AR1FURINSIRT6 | |
| SCHEMBL20375788 | 1.00 | SIRT5 (0.36) | SIRT5KISS1RC3AR1FURINSIRT6 | |
| SCHEMBL16091799 | 1.00 | SIRT5 (0.36) | SIRT5KISS1RC3AR1FURINSIRT6 | |
| SCHEMBL23393940 | 0.93 | SIRT5 (0.39) | SIRT5C3AR1FURINLMNAPOLB | |
| SCHEMBL25092038 | 0.89 | SIRT5 (0.44) | SIRT5KISS1RC3AR1FURINSIRT6 | |
| SCHEMBL17993275 | 0.89 | SIRT5 (0.44) | SIRT5KISS1RC3AR1FURINSIRT6 | |
| SCHEMBL24490420 | 0.89 | C3AR1 (0.34) | SIRT5C3AR1FURINSIRT6SIRT1 | |
| SCHEMBL20795891 | 0.89 | FURIN (0.36) | SIRT5C3AR1FURINSIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024121632-A1 | USE OF ANTI-CD117 ANTIBODY DRUG CONJUGATE (ADC) | CRISPR THERAPEUTICS AG (CH) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024064771-A1 | ANTI-CD45-IGN ANTIBODY DRUG CONJUGATES AND USES THEREOF | VOR BIOPHARMA INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024036329-A2 | CYTOTOXIC COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2024020164-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225320-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-20230049752-A1 | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-02-16 | — | — | US | disclosed |
| WO-2023002415-A2 | METHODS AND COMPOSITIONS FOR ANTI-CD117 ANTIBODY DRUG CONJUGATE (ADC) TREATMENT | Magenta Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022115477-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-9585970-B2 | Site-specific labeling methods and molecules produced thereby | NOVARTIS AG (CH) | 2017-03-07 | — | — | US | disclosed |
| US-9498540-B2 | Cell proliferation inhibitors and conjugates thereof | NOVARTIS AG (CH) | 2016-11-22 | — | — | US | disclosed |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160067351-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| WO-2015138615-A2 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | IRM LLC (BS) | 2015-09-17 | — | — | WO | disclosed |
| US-20150104468-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | IRM LLC (BM) | 2015-04-16 | — | — | US | disclosed |
| US-20140322247-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | disclosed |
| WO-2014124316-A2 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | IRM LLC (BM) | 2014-08-14 | — | — | WO | disclosed |
| US-20140065171-A1 | Site-Specific Labeling Methods and Molecules Produced Thereby | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150104468-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | PTMS, DNPEP, PSAT1 | SIRT5 2967/4885KISS1R 4434/4885C3AR1 2583/4885 |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | SIRT5 3869/4885KISS1R 3017/4885C3AR1 110/4885 |
| US-20160067351-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | PTMS, FCGR2A, FCGR3B | SIRT5 974/4885KISS1R 3987/4885C3AR1 743/4885 |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | AURKC, AURKA, AURKB | SIRT5 1447/4885KISS1R 1962/4885C3AR1 455/4885 |
| US-20140322247-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | MKI67, CCNI, PA2G4 | SIRT5 1235/4885KISS1R 4510/4885C3AR1 3173/4885 |
| US-20140065171-A1 | Site-Specific Labeling Methods and Molecules Produced Thereby | PTMS, DNPEP, PSAT1 | SIRT5 2475/4885KISS1R 4190/4885C3AR1 2062/4885 |
| US-20230049752-A1 | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | EPCAM, LY96, CD2BP2 | SIRT5 4770/4885KISS1R 4595/4885C3AR1 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.